Guiyang Xintian Pharmaceutical Co Ltd
Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of new Chinese patent medicines in China. The company offers products in various dosage forms, including hard capsules, mixtures, granules, gels, tablets, syrups, wine preparation, dews preparations, and two Chinese medicine preparation production lines. Its products are used for the treatment of… Read more
Guiyang Xintian Pharmaceutical Co Ltd (002873) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.039x
Based on the latest financial reports, Guiyang Xintian Pharmaceutical Co Ltd (002873) has a cash flow conversion efficiency ratio of 0.039x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥48.81 Million) by net assets (CN¥1.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guiyang Xintian Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Guiyang Xintian Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Guiyang Xintian Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guiyang Xintian Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SGL Carbon SE
PINK:SGLFF
|
0.025x |
|
Chalice Mining Limited
PINK:CGMLF
|
-0.069x |
|
AUTOHELLAS S.A.NA EO 108
F:0AH1
|
N/A |
|
Contrel Technology Co Ltd
TWO:8064
|
0.011x |
|
ABC arbitrage SA
PA:ABCA
|
0.075x |
|
China-Singapore Suzhou Industrial Park Development Group Co Ltd
SHG:601512
|
0.010x |
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
0.023x |
|
Impax Asset Management Group plc
PINK:IPXAF
|
0.186x |
Annual Cash Flow Conversion Efficiency for Guiyang Xintian Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.19 Billion | CN¥88.13 Million | 0.074x | +5.59% |
| 2023-12-31 | CN¥1.11 Billion | CN¥77.78 Million | 0.070x | +4.05% |
| 2022-12-31 | CN¥1.13 Billion | CN¥75.82 Million | 0.067x | -51.90% |
| 2021-12-31 | CN¥890.44 Million | CN¥124.30 Million | 0.140x | -34.22% |
| 2020-12-31 | CN¥828.30 Million | CN¥175.77 Million | 0.212x | +345.92% |
| 2019-12-31 | CN¥708.76 Million | CN¥33.73 Million | 0.048x | -33.95% |
| 2018-12-31 | CN¥660.59 Million | CN¥47.59 Million | 0.072x | -27.78% |
| 2017-12-31 | CN¥622.11 Million | CN¥62.06 Million | 0.100x | -54.60% |
| 2016-12-31 | CN¥279.21 Million | CN¥61.34 Million | 0.220x | +22.08% |
| 2015-12-31 | CN¥226.31 Million | CN¥40.73 Million | 0.180x | -8.09% |
| 2014-12-31 | CN¥190.50 Million | CN¥37.30 Million | 0.196x | +122.05% |
| 2013-12-31 | CN¥157.38 Million | CN¥13.88 Million | 0.088x | -26.49% |
| 2012-12-31 | CN¥178.44 Million | CN¥21.41 Million | 0.120x | -- |